Genflow's SLAB trial demonstrated that SIRT6 gene therapy reduced biological age in aging beagles, as measured by methylation clocks, compared to saline controls across multiple treatment modalities. This result advances the translation of senolytic and rejuvenation approaches from cell models to living organisms, establishing feasibility for age-reversal interventions in mammalian aging.
Key Points
- SIRT6 naked DNA therapy reduced biological age in treated beagles versus controls
- Both DNA and AAV8 delivery methods showed efficacy in the randomized blinded design
- Methylation clock improvement sustained at three-month follow-up with documented safety
Longevity Analysis
This trial addresses a critical gap in longevity research: demonstrating that genetic interventions targeting cellular senescence and metabolic regulation can produce measurable reversal of aging markers in a living system. The use of methylation clocks as an objective readout bridges the gap between mechanistic understanding of aging at the cellular level and functional outcomes in intact organisms. Because aging involves progressive deterioration across multiple interdependent functions—energy production, regeneration, hormonal signaling, and stress response capacity—showing improvement in a biological age metric suggests coordinated restoration rather than isolated effect. The consistent results across two delivery platforms indicates the therapeutic approach has robustness, not delivery dependency. For practitioners and researchers evaluating longevity interventions, this establishes a proof-of-concept that genetic manipulation of conserved aging pathways can reverse, not merely sl
Original published by LT Wire.